To date, several AURKA inhibitors have successfully reached to the clinical trials for the treatment of diverse cancers including leukemia, triple-negative breast cancer, and prostate cancer [15,16]; Most of the clinically effective AURKA inhibitors were ATP-competitive inhibitors, with IC50 values lying typically in the sub-nanomolar range [15,16]. This evidence concerns the gene AURKA and prostate cancer.